首页> 外文期刊>The Journal of craniofacial surgery >Appraisal of efficacy and safety of intralesional injection of high concentration of bleomycin A5 for treatment of huge macrocystic lymphatic malformations in cervical region.
【24h】

Appraisal of efficacy and safety of intralesional injection of high concentration of bleomycin A5 for treatment of huge macrocystic lymphatic malformations in cervical region.

机译:病灶内高浓度博莱霉素A5内注射治疗宫颈区域巨大的大囊性淋巴畸形的疗效和安全性评估。

获取原文
获取原文并翻译 | 示例
           

摘要

The objective of this study was to investigate the therapeutic effects and safety of intralesional injection of high concentration of bleomycin A5 for huge (more than 5 cm in diameter) macrocystic lymphatic malformations (LMs) in the cervical region. Thirty-two patients with huge macrocystic LMs were treated with percutaneous injection of bleomycin A5 in our department between 2006 and 2011. Among them, 13 patients had unilateral submandibular lesions, and 19 patients had lesions in anterior cervical regions. The age of patients ranged from 10 months to 29 years (mean age, 11.4 y). The concentration of the drug was as high as 2.7 mg/mL (8 mg/3 mL) with an addition of dexamethasone. The mean sessions of injection were 1.6 (1-3 sessions). Repeated injection interval was 4 to 6 weeks. The follow-up period was 6 months to 4 years after the last treatment, and the mean follow-up time was 18 months. The results were evaluated based on clinical examination and Doppler ultrasonography scan. The clinical follow-up showed excellent response in 28 of the 32 patients, whereas 4 of the 32 patients also had a satisfactory response. No serious complications were encountered. Intralesional injection of high concentration of bleomycin A5 was an effective and safe treatment of huge macrocystic LMs in the cervical region and can obtain satisfactory results esthetically and functionally without surgery.
机译:这项研究的目的是调查病灶内注射高浓度的博来霉素A5对宫颈区域巨大(直径超过5厘米)大囊性淋巴畸形(LM)的治疗效果和安全性。 2006年至2011年间,我科经皮注射博来霉素A5治疗了32例大囊性大囊肿患者,其中单侧颌下病变13例,颈前部病变19例。患者的年龄为10个月至29岁(平均年龄11.4岁)。加入地塞米松后,药物浓度高达2.7 mg / mL(8 mg / 3 mL)。注射的平均时间为1.6次(1-3次)。重复注射间隔为4至6周。随访时间为末次治疗后6个月至4年,平均随访时间为18个月。根据临床检查和多普勒超声检查结果对结果进行评估。临床随访显示32例患者中有28例反应良好,而32例患者中有4例反应良好。没有遇到严重的并发症。腹腔内注射高浓度的博来霉素A5是对宫颈区域巨大的大囊性LM的有效且安全的治疗方法,无需手术即可在美学和功能上获得令人满意的结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号